Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, Its Lead Cis-Targeted Il-2 Immunotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, its Lead Cis-targeted IL-2 Immunotherapy

Click to view original post